Skip to main content
Inventiva logo

Inventiva — Investor Relations & Filings

Ticker · IVA ISIN · FR0013233012 LEI · 969500I9Y690B3FZW590 PA Manufacturing
Open in API
Filings indexed 688 across all filing types
Latest filing 2022-01-14 Regulatory Filings
Country FR France
Listing PA IVA

About Inventiva

https://inventivapharma.com/

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrotic diseases, lysosomal storage disorders, and oncology. Its lead product candidate, lanifibranor, is a pan-PPAR (peroxisome proliferator-activated receptor) agonist being evaluated in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is designed to address the key features of NASH, including steatosis, inflammation, ballooning, and fibrosis. The candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) based on positive Phase IIb results.

Recent filings

Filing Released Lang Actions
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Regulatory Filings Classification · 95% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE - Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux" and details the status of a liquidity contract as of December 31, 2021, comparing it to the previous half-year report (June 30, 2021). This content relates to the management and execution of the company's share trading/liquidity arrangements, which often involves the company transacting in its own shares (repurchases/sales under the contract). While it touches upon share activity, the core subject is the reporting of the liquidity contract status, which is a specific form of transaction in own shares. The closest fit among the provided definitions is 'Transaction in Own Shares' (POS), as liquidity contracts are mechanisms for share repurchase/stabilization programs. It is not a full financial report (IR/10-K), an earnings release (ER), or a general regulatory filing (RNS).
2022-01-14 English
Inventiva to present at the 40th Annual J.P. Morgan Healthcare Conference
Investor Presentation Classification · 99% confidence The document is an announcement stating that the company, Inventiva, will present at the 40th Annual J.P. Morgan Healthcare Conference. It provides the date, time, and format of the presentation and Q&A session, and directs readers to the company website for the live link. This type of announcement, which details participation in an external investor event (like a conference presentation), is best classified as an Investor Presentation (IP) announcement or, more broadly, a communication aimed at investors regarding future engagement. Since the document itself is the announcement of participation in an event where presentations will be given, and it includes a corporate overview, it aligns closely with the intent of an Investor Presentation (IP). It is not a formal regulatory filing (like 10-K or IR), nor is it a general regulatory announcement (RNS), as it is highly specific to investor relations activities.
2021-12-16 English
Inventiva annonce sa participation à la « 40th Annual J.P. Morgan Healthcare Conference »
Report Publication Announcement Classification · 99% confidence The document is an announcement by the company Inventiva stating its participation in the '40th Annual J.P. Morgan Healthcare Conference' scheduled for January 2022. It details the date, time, and format of the presentation and Q&A session, and directs readers to the investor relations section for the link. This type of communication, which announces the company's presence and presentation schedule at an external industry event (like a major healthcare conference), is typically classified as an Investor Presentation (IP) if the presentation materials themselves were attached, or, more commonly when it's just the announcement of attendance and schedule, it relates closely to investor outreach. Since the document itself is an announcement about management presenting key company information (pipeline, strategy) at an investor-focused conference, it strongly aligns with the purpose of an Investor Presentation (IP) or a general communication aimed at investors regarding future engagement. Given the context of presenting company activities and pipeline updates at a major investor conference, 'Investor Presentation (IP)' is the most fitting category, even though this specific text is the announcement of attendance rather than the presentation slides themselves. It is not a formal regulatory filing (10-K, IR, ER) nor a simple notice of dividend or management change. It is a proactive communication about investor engagement.
2021-12-16 French
Inventiva annonce les résultats positifs de l’étude clinique « thorough » QT menée avec lanifibranor
Earnings Release Classification · 95% confidence The document is a press release from Inventiva, a biopharmaceutical company, announcing positive results from a clinical study ('thorough' QT study) for their drug candidate, lanifibranor, specifically to support a New Drug Application (NDA) package submission to the FDA. This type of announcement, detailing clinical trial outcomes and regulatory milestones (like supporting an NDA), is characteristic of an Earnings Release (ER) or a general press release related to operational/clinical progress. Since it is an initial announcement of key results (positive QT study outcome) rather than a comprehensive periodic financial report (like 10-K or IR), the most appropriate classification is 'Earnings Release' (ER), as these often include significant operational updates alongside or instead of pure financial figures, especially for clinical-stage biotechs. It is not a full transcript (CT), a formal annual report (10-K), or a general regulatory filing (RNS) that lacks specific content context. It is a direct announcement of results, fitting the ER definition best among the options. FY 2021
2021-12-06 French
Inventiva announces positive results of clinical thorough QT study conducted with lanifibranor
Regulatory Filings Classification · 95% confidence The document is a press release dated December 6, 2021, announcing positive results from a clinical thorough QT study for the drug lanifibranor. It details trial design, endpoints, and quotes the Chief Medical Officer. This format—a news announcement summarizing key clinical or operational developments, often referencing regulatory requirements (like FDA guidance) but not being the full regulatory filing itself—is characteristic of an Earnings Release (ER) or a general press release. Since it is announcing specific clinical trial results and safety data, it is most closely aligned with the function of an Earnings Release (ER) which often includes operational highlights, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. However, given the structure (headline, bullet points of key findings, detailed narrative, boilerplate 'About' sections, and contact info), it functions as a primary announcement of material information, fitting the 'ER' definition (Initial announcement of periodical/key results). It is not a full financial report (10-K or IR), a transcript (CT), or a presentation (IP). It is a direct announcement of results, making ER the best fit among the options provided, although RNS is a possibility if ER is strictly reserved for financial earnings. Given the content is clinical trial results, ER is often used for such material updates in the pharma sector, but since it's not explicitly 'quarterly/periodical financial results', RNS (General regulatory announcements/fallback) is also a strong candidate. I will lean towards ER as it announces a significant 'result' update, which often accompanies or substitutes for a formal earnings report in biotech press releases, but RNS is the safest fallback. Let's re-evaluate the definitions. ER is 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is a clinical result, not financial results. Therefore, RNS (General regulatory announcements and fallback category for miscellaneous filings that do not neatly fit into other specific categories) is the most appropriate classification for a material clinical trial update press release that doesn't fit the financial or specific report categories.
2021-12-06 English
Inventiva publie ses informations financières du 3ème trimestre 2021
Earnings Release Classification · 99% confidence The document is titled "Inventiva publie ses informations financières du 3ème trimestre 2021" (Inventiva publishes its 3rd quarter 2021 financial information) and details the company's cash position and revenue for the first nine months of 2021, which corresponds to the third quarter reporting period. It provides detailed financial metrics (cash, revenue, R&D costs, financing activities) and clinical trial updates. This content structure—a comprehensive financial update for an interim period (Q3) that is more detailed than a simple press release (ER) but not the full annual filing (10-K)—strongly indicates an Interim/Quarterly Report. The French context suggests this is the equivalent of a quarterly report filing, which maps to the 'IR' (Interim / Quarterly Report) code in the provided definitions. The document length (15,208 chars) is substantial, confirming it is the report content itself, not just an announcement of publication (RPA/RNS). 9M 2021
2021-11-10 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.